Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eikon Therapeutics, Inc.EIKN · Entity 5380 | Director | March 02, 2026 | March 04, 2026 |
| Merck & Co., Inc.MRK · Entity 2807 | Director · Executive Chair | November 07, 2022 | November 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eikon Therapeutics, Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.88 · Expires 2036-03-01 | Direct | 25,873 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 25,873 · Balance 25,873 F1: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date.
Merck & Co., Inc.
Report date November 07, 2022 · Filed November 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 936,422.063 |
Reported balance
After 2022-11-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-11-07 · Exercise / conversion · Acquired 235,769 · Balance 936,422.063 |
| Common StockSEC Table I · non-derivative | Direct | 911,508.063 |
Reported balance
After 2022-11-07 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-11-07 · Sale · Disposed 24,914 · Balance 911,508.063 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.7400 to $98.7400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 785,374.063 |
Reported balance
After 2022-11-07 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2022-11-07 · Sale · Disposed 126,134 · Balance 785,374.063 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.7500 to $99.7500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 700,653.063 |
Reported balance
After 2022-11-07 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2022-11-07 · Sale · Disposed 84,721 · Balance 700,653.063 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.7600 to $100.3400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F4: Holdings include shares acquired in dividend reinvestment transactions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.06 · Expires 2026-05-09 | Direct | 0 |
Reported balance
After 2022-11-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-11-07 · Exercise / conversion · Disposed 235,769 · Balance 0 F6: The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. |
| Common Stock - 401(k) PlanSEC Table I · non-derivative | IndirectBy 401(k) | 4,481.1286 |
Reported balance
Holding disclosure · report date 2022-11-07 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 4,481.1286 F5: Includes shares acquired and dividends earned through October 7, 2022 in the Merck U.S. Savings Plan, a 401(k) plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.7400 to $98.7400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.7500 to $99.7500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.7600 to $100.3400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F4: Holdings include shares acquired in dividend reinvestment transactions.
F5: Includes shares acquired and dividends earned through October 7, 2022 in the Merck U.S. Savings Plan, a 401(k) plan.
F6: The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
EXXON MOBIL CORP
Report date May 25, 2022 · Filed May 26, 2022
Section 16 reporting ended · disclosed 2022-05-26. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 10, 2014 Filed Nov 10, 2014 21:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 9,333 | $0.00 Strike: $35.09 | $0.00 |
DisclosureSEC source: 0001225208-14-023001 · doc4.xml · derivative · entry 6 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,332 Underlying: Common Stock · 9,333 shares Expires 2016-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option became exercisable in equal installments on 3/3/2007, 3/3/2008 and 3/3/2009. Read SEC document |
| November 10, 2014 Filed Nov 10, 2014 21:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 3,542 | $0.00 Strike: $31.84 | $0.00 |
DisclosureSEC source: 0001225208-14-023001 · doc4.xml · derivative · entry 5 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,164 Underlying: Common Stock · 3,542 shares Expires 2015-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 2/25/2006, 2/25/2007 and 2/25/2008. Read SEC document |
| November 10, 2014 Filed Nov 10, 2014 21:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 10,000 | $57.98 | $579,784.00 |
DisclosureSEC source: 0001225208-14-023001 · doc4.xml · nonDerivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,420.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.7100 to $58.2300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 10, 2014 Filed Nov 10, 2014 21:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 3,542 | $31.84 | $112,777.28 |
DisclosureSEC source: 0001225208-14-023001 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,420.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2014 Filed Nov 10, 2014 21:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 9,333 | $35.09 | $327,494.97 |
DisclosureSEC source: 0001225208-14-023001 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,878.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 10, 2014 Filed Oct 14, 2014 13:05 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 9,333 | $0.00 Strike: $35.09 | $0.00 |
DisclosureSEC source: 0001225208-14-021558 · doc4.xml · derivative · entry 6 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,665 Underlying: Common Stock · 9,333 shares Expires 2016-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option became exercisable in equal installments on 3/3/2007, 3/3/2008 and 3/3/2009. Read SEC document |
| October 10, 2014 Filed Oct 14, 2014 13:05 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 3,542 | $0.00 Strike: $31.84 | $0.00 |
DisclosureSEC source: 0001225208-14-021558 · doc4.xml · derivative · entry 5 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,706 Underlying: Common Stock · 3,542 shares Expires 2015-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 2/25/2006, 2/25/2007 and 2/25/2008. Read SEC document |
| October 10, 2014 Filed Oct 14, 2014 13:05 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 9,895 | $59.73 | $591,033.30 |
DisclosureSEC source: 0001225208-14-021558 · doc4.xml · nonDerivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,545.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.3600 to $59.8600, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| October 10, 2014 Filed Oct 14, 2014 13:05 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 3,542 | $31.84 | $112,777.28 |
DisclosureSEC source: 0001225208-14-021558 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,440.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 10, 2014 Filed Oct 14, 2014 13:05 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 9,333 | $35.09 | $327,494.97 |
DisclosureSEC source: 0001225208-14-021558 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,898.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2014 Filed Sep 10, 2014 17:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 9,333 | $0.00 Strike: $35.09 | $0.00 |
DisclosureSEC source: 0001225208-14-019661 · doc4.xml · derivative · entry 6 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,998 Underlying: Common Stock · 9,333 shares Expires 2016-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option became exercisable in equal installments on 3/3/2007, 3/3/2008 and 3/3/2009. Read SEC document |
| September 10, 2014 Filed Sep 10, 2014 17:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 3,542 | $0.00 Strike: $31.84 | $0.00 |
DisclosureSEC source: 0001225208-14-019661 · doc4.xml · derivative · entry 5 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,248 Underlying: Common Stock · 3,542 shares Expires 2015-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 2/25/2006, 2/25/2007 and 2/25/2008. Read SEC document |
| September 10, 2014 Filed Sep 10, 2014 17:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 9,814 | $60.48 | $593,591.94 |
DisclosureSEC source: 0001225208-14-019661 · doc4.xml · nonDerivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,565.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.3700 to $60.6400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| September 10, 2014 Filed Sep 10, 2014 17:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 3,542 | $31.84 | $112,777.28 |
DisclosureSEC source: 0001225208-14-019661 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,379.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2014 Filed Sep 10, 2014 17:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 9,333 | $35.09 | $327,494.97 |
DisclosureSEC source: 0001225208-14-019661 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,837.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2014 Filed Aug 12, 2014 13:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 9,333 | $0.00 Strike: $35.09 | $0.00 |
DisclosureSEC source: 0001225208-14-018293 · doc4.xml · derivative · entry 6 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,331 Underlying: Common Stock · 9,333 shares Expires 2016-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 3/3/2007, 3/3/2008 and 3/3/2009. Read SEC document |
| August 11, 2014 Filed Aug 12, 2014 13:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 3,542 | $0.00 Strike: $31.84 | $0.00 |
DisclosureSEC source: 0001225208-14-018293 · doc4.xml · derivative · entry 5 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,790 Underlying: Common Stock · 3,542 shares Expires 2015-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option became exercisable in equal installments on 2/25/2006, 2/25/2007 and 2/25/2008. Read SEC document |
| August 11, 2014 Filed Aug 12, 2014 13:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 10,058 | $57.00 | $573,306.00 |
DisclosureSEC source: 0001225208-14-018293 · doc4.xml · nonDerivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,504.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| August 11, 2014 Filed Aug 12, 2014 13:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 3,542 | $31.84 | $112,777.28 |
DisclosureSEC source: 0001225208-14-018293 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,562.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2014 Filed Aug 12, 2014 13:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 9,333 | $35.09 | $327,494.97 |
DisclosureSEC source: 0001225208-14-018293 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,020.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2014 Filed Aug 8, 2014 20:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | GiftCommon Stock | 8,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-14-018205 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,687.063 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| July 10, 2014 Filed Jul 10, 2014 19:47 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 9,334 | $0.00 Strike: $35.09 | $0.00 |
DisclosureSEC source: 0001225208-14-016850 · doc4.xml · derivative · entry 6 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,664 Underlying: Common Stock · 9,334 shares Expires 2016-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option became exercisable in equal installments on 3/3/2007, 3/3/2008 and 3/3/2009. Read SEC document |
| July 10, 2014 Filed Jul 10, 2014 19:47 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 3,542 | $0.00 Strike: $31.84 | $0.00 |
DisclosureSEC source: 0001225208-14-016850 · doc4.xml · derivative · entry 5 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,332 Underlying: Common Stock · 3,542 shares Expires 2015-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 2/25/2006, 2/25/2007 and 2/25/2008. Read SEC document |
| July 10, 2014 Filed Jul 10, 2014 19:47 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 9,987 | $58.03 | $579,544.61 |
DisclosureSEC source: 0001225208-14-016850 · doc4.xml · nonDerivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,487.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.7600 to $58.3800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| July 10, 2014 Filed Jul 10, 2014 19:47 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 3,542 | $31.84 | $112,777.28 |
DisclosureSEC source: 0001225208-14-016850 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,474.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2014 Filed Jul 10, 2014 19:47 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 9,334 | $35.09 | $327,530.06 |
DisclosureSEC source: 0001225208-14-016850 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,932.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2014 Filed Jun 11, 2014 18:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 9,334 | $0.00 Strike: $35.09 | $0.00 |
DisclosureSEC source: 0001225208-14-014834 · doc4.xml · derivative · entry 6 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,998 Underlying: Common Stock · 9,334 shares Expires 2016-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2014 Filed Jun 11, 2014 18:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 3,542 | $0.00 Strike: $31.84 | $0.00 |
DisclosureSEC source: 0001225208-14-014834 · doc4.xml · derivative · entry 5 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,874 Underlying: Common Stock · 3,542 shares Expires 2015-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2014 Filed Jun 11, 2014 18:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 9,985 | $58.06 | $579,753.06 |
DisclosureSEC source: 0001225208-14-014834 · doc4.xml · nonDerivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,598.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.9600 to $58.2700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| June 10, 2014 Filed Jun 11, 2014 18:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 3,542 | $31.84 | $112,777.28 |
DisclosureSEC source: 0001225208-14-014834 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,583.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2014 Filed Jun 11, 2014 18:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 9,334 | $35.09 | $327,530.06 |
DisclosureSEC source: 0001225208-14-014834 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,041.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2014 Filed May 13, 2014 19:56 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 550,206 | $0.00 Strike: $58.22 | $0.00 |
DisclosureSEC source: 0001225208-14-012827 · doc4.xml · derivative · entry 7 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,206 Underlying: Common Stock · 550,206 shares Expires 2024-05-08 F4 · derivative.exercise_date: The option vests in three equal annual installments beginning May 9, 2015. Read SEC document |
| May 09, 2014 Filed May 13, 2014 19:56 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 9,334 | $0.00 Strike: $35.09 | $0.00 |
DisclosureSEC source: 0001225208-14-012827 · doc4.xml · derivative · entry 6 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,332 Underlying: Common Stock · 9,334 shares Expires 2016-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2014 Filed May 13, 2014 19:56 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 3,542 | $0.00 Strike: $31.84 | $0.00 |
DisclosureSEC source: 0001225208-14-012827 · doc4.xml · derivative · entry 5 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,416 Underlying: Common Stock · 3,542 shares Expires 2015-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2014 Filed May 13, 2014 19:56 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 10,220 | $55.00 | $562,100.00 |
DisclosureSEC source: 0001225208-14-012827 · doc4.xml · nonDerivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,707.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 09, 2014 Filed May 13, 2014 19:56 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 3,542 | $31.84 | $112,777.28 |
DisclosureSEC source: 0001225208-14-012827 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,927.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2014 Filed May 13, 2014 19:56 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 9,334 | $35.09 | $327,530.06 |
DisclosureSEC source: 0001225208-14-012827 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,385.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2014 Filed May 6, 2014 20:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 41,028 | $58.22 | $2,388,650.16 |
DisclosureSEC source: 0001225208-14-012265 · doc4.xml · derivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 41,028 shares Expires 2014-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 04, 2014 Filed May 6, 2014 20:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 18,471 | $58.22 | $1,075,381.62 |
DisclosureSEC source: 0001225208-14-012265 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,051.063 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 04, 2014 Filed May 6, 2014 20:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 41,028 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-14-012265 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,522.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 10, 2014 Filed Apr 11, 2014 13:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 9,334 | $0.00 Strike: $35.09 | $0.00 |
DisclosureSEC source: 0001225208-14-010549 · doc4.xml · derivative · entry 7 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,666 Underlying: Common Stock · 9,334 shares Expires 2016-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 10, 2014 Filed Apr 11, 2014 13:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 3,542 | $0.00 Strike: $31.84 | $0.00 |
DisclosureSEC source: 0001225208-14-010549 · doc4.xml · derivative · entry 6 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,958 Underlying: Common Stock · 3,542 shares Expires 2015-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 10, 2014 Filed Apr 11, 2014 13:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 6,706 | $57.14 | $383,204.98 |
DisclosureSEC source: 0001225208-14-010549 · doc4.xml · nonDerivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,494.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.9500 to $57.2118, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F4 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| April 10, 2014 Filed Apr 11, 2014 13:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 3,341 | $57.44 | $191,903.03 |
DisclosureSEC source: 0001225208-14-010549 · doc4.xml · nonDerivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,200.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.2155 to $58.0200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| April 10, 2014 Filed Apr 11, 2014 13:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 3,542 | $31.84 | $112,777.28 |
DisclosureSEC source: 0001225208-14-010549 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,541.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 10, 2014 Filed Apr 11, 2014 13:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 9,334 | $35.09 | $327,530.06 |
DisclosureSEC source: 0001225208-14-010549 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,999.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2014 Filed Feb 26, 2014 19:24 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 44,836 | $56.18 | $2,518,886.48 |
DisclosureSEC source: 0001225208-14-006287 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,665.063 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 03/31/2011. Performance shares were paid out at 86 percent of target awards. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 11, 2014 Filed Feb 11, 2014 22:34 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $48.24 | $0.00 |
DisclosureSEC source: 0001225208-14-004138 · doc4.xml · derivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2014-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2014 Filed Feb 11, 2014 22:34 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 41,520 | $54.52 | $2,263,682.86 |
DisclosureSEC source: 0001225208-14-004138 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,829.063 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.47 to $54.60, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 11, 2014 Filed Feb 11, 2014 22:34 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 45,000 | $48.24 | $2,170,800.00 |
DisclosureSEC source: 0001225208-14-004138 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,349.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.